Eplontersen sodium is under clinical development by AstraZeneca and currently in Phase III for Familial Amyloid Cardiomyopathy. According to GlobalData, Phase III drugs for Familial Amyloid Cardiomyopathy have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Eplontersen sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Eplontersen sodium overview
Eplontersen sodium (Wainua) is an aldosterone receptor agent. It is formulated as a solution for the subcutaneous route of administration. Wainua is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
AKCEA-TTR-LRx is under development for the treatment of familial amyloid polyneuropathy (FAP/hereditary transthyretin amyloidosis) and transthyretin mediated amyloid cardiomyopathy. It is administered through subcutaneous route. The drug candidate acts by targeting transthyretin (TTR) protein. It is developed based on ligand conjugated antisense technology (LICA) platform.
AstraZeneca overview
AstraZeneca is a biopharmaceutical company, that focuses on the discovery, production, and commercialization of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa, and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Eplontersen sodium’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
